Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

Annals of Neurology

Volumn 60, Issue 2, 2006, Pages 162-173

  Koralnik, Igor J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ALPHA4 INTEGRIN; ANTIRETROVIRUS AGENT; BETA1A INTERFERON; CAPSID PROTEIN; CIDOFOVIR; CREATINE; CYTARABINE; DIDANOSINE; FLUDARABINE; HLA A ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INOSITOL; MIRTAZAPINE; NATALIZUMAB; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; STAVUDINE; STEROID; TOPOTECAN; VIRUS DNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; BRAIN BIOPSY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; GRANULE CELL; HEMATOLOGIC MALIGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATORY DISEASE; JC VIRUS; LIVER CIRRHOSIS; LUNG FIBROSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SARCOIDOSIS; THROMBOCYTOPENIA; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS LATENCY; VIRUS MENINGITIS; VIRUS REACTIVATION;

BIOLOGICAL MARKERS; BRAIN; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK; TERMINOLOGY;

EID: 33746825429     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20933     Document Type: Review

References (115)

1. Astrom KE, Mancall EL, Richardson EP. Progressive multifocal leukoencephalopathy. Brain 1958;81:93-127.
2. Cavanaugh JB, Greenbaum D, Marshall A, Rubinstein L. Cerebral demyelination associated with disorders of the reticuloendothelial system. Lancet 1959:524-529.
3. Zu Rhein GM, Chou S-M. Particles resembling papova viruses in human cerebral demyelinating disease. Science 1965; 148:1477-1479.
4. Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971;1:1257-1260.
5. Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC virus genome. J Virol 1984;51:458-469.
6. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin 1984;2:299-313.
7. Miller JR, Barrett RE, Britton CB, et al. Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med 1982;307:1436-1438.
8. Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987;107:78-87.
9. Power C, Gladden JG, Halliday W, et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 2000;54:743-746.
10. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002;8(suppl 2):115-121.
11. US Food and Drug Administration. FDA approves resumed marketing of Tysabri under a special distribution program. FDA News, 2006.
12. Berger JR, Miller CS, Mootoor Y, et al. JC virus detection in bodily fluids: clues to transmission. Clin Infect Dis 2006;43: e9-e12.
13. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71:115-123.
14. Hamilton RS, Gravell M, Major EO. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 2000;38:105-109.
15. Stolt A, Sasnauskas K, Koskela P, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003;84:1499-1504.
16. Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997;176:250-254.
17. Viscidi RP, Rollison DE, Viscidi E, et al. Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 2003;10:278-285.
18. Kitamura T, Aso Y, Kuniyoshi N, et al. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J Infect Dis 1990;161:1128-1133.
19. Koralnik IJ, Boden D, Mai VX, et al. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999;52:253-260.
20. Monaco MC, Jensen PN, Hou J, et al. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 1998;72:9918-9923.
21. Houff SA, Major EO, Katz DA, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988;318:301-305.
22. Katz DA, Berger JR, Hamilton B, et al. Progressive multifocal leukoencephalopathy complicating Wiskott-Aldrich syndrome. Report of a case and review of the literature of progressive multifocal leukoencephalopathy with other inherited immunodeficiency states. Arch Neurol 1994;51:422-426.
23. Tornatore C, Berger JR, Houff SA, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 1992;31:454-462.
24. Schneider EM, Dorries K. High frequency of polyomavirus infection in lymphoid cell preparations after allogeneic bone marrow transplantation. Transplant Proc 1993;25:1271-1273.
25. Coppo P, Laporte JP, Aoudjhane M, et al. Progressive multifocal leucoencephalopathy with peripheral demyelinating neuropathy after autologous bone marrow transplantation for acute myeloblastic leukemia (FAB5). Bone Marrow Transplant 1999;23:401-403.
26. Ricciardiello L, Laghi L, Ramamirtham P, et al. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology 2000;119: 1228-1235.
27. Newcomb PA, Bush AC, Stoner GL, et al. No evidence of an association of JC virus and colon neoplasia. Cancer Epidemiol Biomarkers Prev 2004;13:662-666.
28. Buckle GJ, Godec MS, Rubi JU, et al. Lack of JC viral genomic sequences in multiple sclerosis brain tissue by polymerase chain reaction. Ann Neurol 1992;32:829-831.
29. White FAd, Ishaq M, Stoner GL, Frisque RJ. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol 1992; 66:5726-5734.
30. Dubois V, Lafon ME, Ragnaud JM, et al. Detection of JC virus DNA in the peripheral blood leukocytes of HIV- infected patients. Aids 1996;10:353-358.
31. Atwood WJ, Amemiya K, Traub R, et al. Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology 1992;190:716-723.
32. Monaco MC, Atwood WJ, Gravell M, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 1996;70:7004-7012.
33. Dubois V, Dutronc H, Lafon ME, et al. Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol 1997; 35:2288-2292.
34. Koralnik IJ, Schmitz JE, Lifton MA, et al. Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected individuals. J Neurovirol 1999;5:430-435.
35. Wei G, Liu CK, Atwood WJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol 2000;6:127-136.
36. Newman JT, Frisque RJ. Detection of archetype and rear-ranged variants of JC virus in multiple tissues from a pediatric PML patient. J Med Virol 1997;52:243-252.
37. Koralnik IJ, Schellingerhout D, Frosch MP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits. N Engl J Med 2004;350:1882-1893.
38. Selik RM, Karon JM, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis 1997; 176:632-636.
39. Aksamit A. Review of PML and natalizumab. The Neurologist. 2006 (in press).
40. Garcia-Suarez J, de Miguel D, Krsnik I, et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferarive disorders: impact of novel therapies. Am J Hematol 2005;80:271-281.
41. Lima MA, Auriel E, Wuthrich C, et al. Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient. Clin Infect Dis 2005; 41:417-419.
42. Lima MA, Drislane F, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 2006;66:262-264.
43. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998;4:59-68.
44. Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003;9(suppl 1):47-53.
45. Whiteman ML, Post MJ, Berger JR, et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993;187:233-240.
46. Post MJ, Yiannoutsos C, Simpson D, et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol 1999;20:1896-1906.
47. Gray F, Geny C, Lescs MC, et al. [AIDS-related progressive multifocal leukoencephalopathy limited to U fibers, responsible for subacute encephalopathy with normal CT scan findings]. Arch Anat Cytol Pathol 1992;40:132-137.
48. Trotot PM, Vazeux R, Yamashita HK, et al. MRI pattern of progressive multifocal leukoencephalopathy (PML) in AIDS. Pathological correlations. J Neuroradiol 1990;17:233-254.
49. Thurnher MM, Post MJ, Rieger A, et al. Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am J Neuroradiol 2001;22:977-984.
50. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003;9(suppl 1):73-80.
51. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003;9(suppl 1):25-31.
52. Vendrely A, Bienvenu B, Gasnault J, et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol (Berl) 2005;109: 449-455.
53. Tagliati M, Simpson D, Morgello S, et al. Cerebellat degeneration associated with human immunodeficiency virus infection. Neurology 1998;50:244-251.
54. Richardson EP Jr, Webster HD. Progressive multifocal leukoencephalopathy: its pathological features. Prog Clin Biol Res 1983;105:191-203.
55. Du Pasquier RA, Corey S, Margolin DH, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003;61:775-782.
56. Tyler KL. The uninvited guest: JC virus infection of neurons in PML. Neurology 2003;61:734-735.
57. Koralnik IJ, Wuthrich C, Dang X, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57:576-580.
58. Dang X, Koralnik IJ. A granule cell neuron-associated JC virus variant has a unique deletion in the VP1 gene. J Gen Virol 2006;87:2533-2537.
59. Simon MA, Ilyinskii PO, Baskin GB, et al. Association of simian virus 40 with a central nervous system lesion distinct from progressive multifocal leukoencephalopathy in macaques with AIDS. Am J Pathol 1999;154:437-446.
60. Blake K, Pillay D, Knowles W, et al. JC virus associated meningoencephalitis in an immunocompetent girl. Arch Dis Child 1992;67:956-957.
61. Skolasky RL, Dal Pan GJ, Olivi A, et al. HIV-associated primary CNS morbidity and utility of brain biopsy. J Neurol Sci 1999;163:32-38.
62. Cinque P, Scarpellini P, Vago L, et al. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. Aids 1997;11:1-17.
63. Marzocchetti A, Di Giambenedetto S, Cingolani A, et al. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005;43:4175-4177.
64. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003;9(suppl 1):88-92.
65. Richardson EP Jr, Johnson PC. Atypical progressive multifocal leukoencephalopathy with plasma-cell infiltrates. Acta Neuropathol Suppl (Berl) 1975;(suppl):247-250.
66. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998;44:341-349.
67. Yiannoutsos CT, Major EO, Curfman B, et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 1999; 45:816-821.
68. Bossolasco S, Calori G, Moretti F, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 2005;40:738-744.
69. Weber F, Goldmann C, Kramer M, et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 2001;49:636-642.
70. Gasnault J, Kahraman M, de Goer de Herve MG, et al. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. Aids 2003;17: 1443-1449.
71. Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001;75:3483-3487.
72. Koralnik IJ, Du Pasquier RA, Kuroda MJ, et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 2002;168: 499-504.
73. Du Pasquier RA, Kuroda MJ, Schmitz JE, et al. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol 2003;77:11918-11926.
74. Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004;127:1970-1978.
75. Du Pasquier RA, Schmitz JE, Jean-Jacques J, et al. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 2004;78:10206-10210.
76. Chang L, Ernst T, Tornatore C, et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997;48: 836-845.
77. Katz-Brull R, Lenkinski RE, Du Pasquier RA, Koralnik IJ. Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy. Neurology 2004;63:897-900.
78. Du Pasquier RA, Autissier P, Zheng Y, et al. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. Aids 2005; 19:2069-2076.
79. + T cells with JCV-infected glial cells. J Neurovirol 2006;12:116-128.
80. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
81. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251:407-413.
82. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
83. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med 2005;353:414-416.
84. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374.
85. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381.
86. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
87. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003;348: 68-72.
88. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368.
89. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-933.
90. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747.
91. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006;59:748-754.
92. Hauset SL, Weiner HL. Natalizumab: immune effects and implications for therapy. Ann Neurol 2006;59:731-732.
93. Major EO, Ryschkewitsch C, Fahle G. The laboratory evaluation for JC virus DNA in CSF and plasma from multiple sclerosis patients participating in the phase III clinical trials of natalizumab. Oral Presentation; Abstract 679. ECTRIMS 2005; Mult Scler 2005;11(Supp 1):S181.
94. Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005; 8:1275.
95. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005;5: 582-594.
96. Chen Y, Trofe J, Gordon J, et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol 2006; 80:3495-3505.
97. Jensen PN, Major EO. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neurovirol 2001;7: 280-287.
98. Pfister L-A, Letvin NL, Koralnik IJ. JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy. J Virol 2001;75: 5672-5676.
99. + cytotoxic T cell response in multiple sclerosis patients. J Neuroimmunol 2006 (in press).
100. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998;338:1345-1351.
101. Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998;4:451-456.
102. Aksamit AJ. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol 2001;7:386-390.
103. Groothuis DR, Benalcazar H, Allen CV, et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res 2000;856:281-290.
104. Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997;41:587-593.
105. Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. Aids 2002;16:1791-1797.
106. Gasnault J, Kousignian P, Kahraman M, et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 2001;7:375-381.
107. Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003;36:1047-1052.
108. Osorio S, de la Camara R, Golbano N, et al. Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir. Bone Marrow Transplant 2002;30:963-966.
109. Herrlinger U, Schwarzler F, Beck R, et al. Progressive multifocal leukoencephalopathy: cidofovir therapy in three patients with underlying hematological disease. J Neurol 2003;250: 612-614.
110. Royal W 3rd, Dupont B, McGuire D, et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 2003;9:411-419.
111. Geschwind MD, Skolasky RI, Royal WS, McArthur JC. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 2001;7:353-357.
112. Miralles P, Berenguer J, Lacruz C, et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. Aids 2001;15:1900-1902.
113. Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004;306:1380-1383.
114. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
115. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.